J Korean Neurosurg Soc 48: 134-138, 2010

#### **Clinical Article**

# Outcome of Pallidal Deep Brain Stimulation in Meige Syndrome

Ju-Young Ghang, M.D.,<sup>1</sup> Myung-Ki Lee, M.D.,<sup>3</sup> Sung-Man Jun, M.D.,<sup>2</sup> Chang-Ghu Ghang, M.D.<sup>1</sup>

Departments of Neurosurgery,<sup>1</sup> Neurology,<sup>2</sup> Bongseng Memorial Hospital, Busan, Korea Department of Neurosurgery,<sup>3</sup> On Hospital, Busan, Korea

**Objective :** Meige syndrome is the combination of blepharospasm and oromandibular dystonia. We assessed the surgical results of bilateral globus pallidus internus (GPi) deep brain stimulation (DBS) in patients with medically refractory Meige syndrome.

**Methods :** Eleven patients were retrospectively analyzed with follow-ups of more than 12 months. The mean follow-up period was  $23.1 \pm 6.4$  months. The mean age at time of surgery was  $58.0 \pm 7.8$  years. The mean duration of symptoms was  $8.7 \pm 7.6$  years. DBS electrodes were placed under local anesthesia using microelectrode recording and stimulation. After  $2.4 \pm 1.3$  days of trial tests, the stimulation device was implanted under general anesthesia. Patients were evaluated using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS).

**Results**: BFMDRS total movement scores improved by 59.8%, 63.5%, 74.1%, 74.5%, and 85.5% during the immediate postoperative period of test stimulation, 3, 6, 12, and 24 months (n = 5) after surgery, respectively. The BFMDRS total movement scores were reduced gradually and the results reached statistical significance in the postoperative period (test period, p < 0.001; 3 months, p < 0.001; 6 months, p = 0.003; 12 months, p < 0.001; 24 months, p = 0.042). There was no statistical difference between 12 months and 24 months. BFM subscores improved by 63.3% for the eyes, 80.9% for the mouth, 68.4% for speech/swallowing, and 87.9% for the neck at 12 months after surgery. The adverse effects were insignificant.

Conclusion : The bilateral GPi-DBS can be effective for the treatment of intractable Meige syndrome without significant side effects.

KEY WORDS : Globus pallidus · Meige syndrome · Deep brain stimulation.

# INTRODUCTION

In 1910, Henry Meige, a French neurologist, coined the term spasme facial median to describe a form of spasmodic torticollis consisting of spontaneous adult-onset dystonic movements of facial muscles causing blepharospasm and a variety of dystonic spasms of the lower face, jaw, and neck<sup>6</sup>. Meige syndrome typically begins in the fifth or sixth decade of life<sup>2</sup>. Frequently, symptoms do not support the benefits of medication or botulinum toxin injections<sup>3,5,10</sup>. There is a growing interest in the use of deep brain stimulation (DBS) in medically refractory forms of dystonia. DBS of the globus pallidus internus (GPi) has been shown to be effective in the

 Address for reprints : Myung-Ki Lee, M.D. Department of Neurosurgery, On Hospital, 966 Danggam-dong, Jin-gu, Busan 614-100, Korea Tel : +82-51-607-0114, Fax : +82-51-607-0220 E-mail : stereomk@naver.com treatment of juvenile and adult onset primary generalized dystonia and segmental dystonia<sup>3,6)</sup>. However, the experience of GPi-DBS in the treatment of segmental cranial dystonia, such as Meige syndrome, is still limited.

In this report, we retrospectively assessed the experiences of 11 patients with medically refractory Meige syndrome. The purpose of this study was to analyze the effect of GPi-DBS in the patients.

## MATERIALS AND METHODS

Between August 2006 and July 2008, 11 patients (9 females and 2 males) met the following criteria : 1) idiopathic cranialcervical dystonia (blepharospasm, lower facial and oromandibular dystonia, with or without the involvement of cervical muscles), 2) severe functional impairment despite medical management, including failed botulinum toxin therapy, 3) absence of secondary causes of dystonia, 4) no history of exposure to neuroleptics, 5) normal neurological exam except for

<sup>•</sup> Received : April 21, 2010 • Revised : July 3, 2010

<sup>•</sup> Accepted : August 3, 2010

dystonia, and 6) normal magnetic resonance imaging (MRI) of the brain. None of the patients had major dementia, a familial history of dystonia, or psychiatric disorders except for one female patient. This patient presented with symptoms of Meige syndrome six years before she was diagnosed as schizophrenia. A MRI of the brain and a medical laboratory evaluation did not reveal abnormal findings, and the neurological examination was normal with the exception of symptoms of Meige syndrome.

The clinical characteristics of the patients are summarized in Table 1. The ages of the patients ranged from 45 to 70 years (mean  $58.0 \pm 7.8$  years). The mean duration of symptoms was  $8.7 \pm 7.6$  years (range 1-20). The dystonia syndrome began with blepharospasm in nine patients and oromandibular dystonia in two patients. Nine patients had cervical dystonia. Three patients had slight pulling cervical dystonia, three patients had mild torticollis, two patients had moderate pulling cervical dystonia, and one patient had extreme pulling cervical dystonia. All of them had mobile or phasic type of the cervical dystonia. Patient 4 had a history of bilateral full-extended myectomy around the upper eyelashes for the treatment of blepharospasm. Patient 5 had a history of double eyelid operation for the treatment of blepharospasm. All patients had received botulinum toxins and medications with no remarkable improvement.

All evaluations were performed by one neurosurgeon and one neurologist using the Burke-Fahn-Marsden Dystonia Scale (BFMDRS) before and every three months after surgery<sup>1)</sup>. The mean follow-up period was  $23.1 \pm 6.4$  months (range 12-35) with bilateral GPi-DBS, and 5 (45.4%) of 11 patients were available for follow-up at 24 months after surgery.

The 11 patients underwent simultaneous bilateral implantation of quadripolar DBS leads (DBS Model 3387, Medtronic) into the GPi under local anesthesia. Electrode implantation was based on indirect and direct targeting using a 1.5tesla MRI (General Electric, USA) and a Neurosurgery Simulator (Dimos, Seoul, Korea) as surgical planning tools refined using microelectrode recording and stimulation (Fig. 1). The initially planned mean target was  $3.0 \pm 0.6$  mm the anterior to the mid-commissural point, 22.2 ± 1.3 mm lateral to the midline, and  $4.0 \pm 0.0$  mm below the anterior commissure-posterior commissure plane. The mean distance between the anterior and posterior commissure was  $22.5 \pm 1.4$ mm. The mean arc and sliding angles were  $61.9 \pm 3.5$  and 5.6 ± 3.1 degrees, respectively. Intraoperative test stimulation using a microelectrode was performed at 1.0 to 5.0 V, 200 µs and 130 Hz to check motor, sensory and visual responses. All patients underwent a postoperative MRI or computed tomography to assess the electrode's position and surgical conditions.

The mean locations of the final 22 electrodes were  $21.6 \pm 1.3$  mm lateral to the midline,  $2.8 \pm 0.7$  mm anterior to the mid-commissural point, and  $4.0 \pm 0.0$  mm below the mid-commissure plane. Fig. 2 shows the final lead location in the axial plane passing through the anterior and posterior commissures. After  $2.4 \pm 1.3$  days (range 1-5) of trial testing




Fig. 1. Microelectrode recordings in the globus pallidus of patient 11. GPe : globus pallidus externa, GPie : external segment of globus pallidus internus, GPii : internal segment of globus pallidus internus.

Na	Sex	Age at	Duration	Site of	Preoperative	BFMDRS at 12 months	Postoperative	Cervical
No.		onset (yr)	of illness (yr)	onset	BFMDRS	after surgery	follow-up(mo)	involvement
1	F	41	20	Е	17	8	35	Yes
2	F	62	4	М	34	10	29	Yes
3	F	43	20 E	24	0	28	Yes	
4	М	51	6	E	17	5.5	25	No
5	F	53	2	E	22	0	24	No
6	F	56	4	E	30	4.5	23	Yes
7	F	37	8	М	20	0	23	Yes
8	F	69	1	E	32	18	20	Yes
9	М	44	3	Е	20	3	19	Yes
10	F	45	8	Е	26	10	16	Yes
11	F	43	20	Е	28	10	12	Yes

Table 1. Clinical characteristics of patients with Meige syndrome

BFMDRS : Burk-Fahn-Marsden dystonia rating scale, E : eye, M : mouth

(Model 3625 external tester, Medtronic Inc.) in the hospital ward, the stimulation device (Soletra, Medtronic Inc.) was implanted subcutaneously in the subclavicular area while the patient was under general anesthesia. The stimulation parameters of the test stimulation were : frequency, 130 Hz; pulse width, 60 (in two patients) or 210 (in nine patients)  $\mu$ s; and amplitude, 2.0 to 3.5 V. The pulse generator was programmed on the first postoperative day. The frequency was set at 60, 130, and 185 Hz, the pulse width was set at 60, 90, 120, 180 and 210  $\mu$ s, and the voltage was set 2.6 to 5.0 V at the last follow-up (Table 2).

The statistical significance of the changes in clinical rating scales at 3, 6, 12, and 24 months after surgery compared with the baseline were assessed using the Wilcoxin signed rank test (paired). A significance threshold of 0.05 was used. We also analyzed preoperative factors to determine which correlated with outcomes in each patient.

Table 2.	. Summary	of patients'	data
----------	-----------	--------------	------

No. of patients11Age at onset (yr) $49.4 \pm 9.7$ (range $37-69$ )Sex-no. (%) $49.4 \pm 9.7$ (range $37-69$ )Male $2$ (18)Female $9$ (82)Duration of illness (yr) $8.7 \pm 7.5$ (range $1-20$ )Site of onset-no. (%) $2$ (18)Eye $9$ (82)Mouth $2$ (18)Stimulation measurements at latest follow-upAmplitude (V) $3.4 \pm 0.6$ (range $2.6-5.0$ )Pulse width (µs) $133.6 \pm 57.4$ (range $60-210$ )Frequency (Hz) $143.1 \pm 38.1$ (range $60-185$ )Follow-up (mo) $23.0 \pm 6.3$ Preoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $49.9 \pm 7.7$ At 6 months after surgery $6.3 \pm 5.6$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$ 12 Mo % improvement from baseline (%) $74.5 \pm 19.8$	rabio El Carinnary of pationito data				
Sex-no. (%) $2$ (18)Male2 (18)Female9 (82)Duration of illness (yr) $8.7 \pm 7.5$ (range 1-20)Site of onset-no. (%) $2$ (18)Eye9 (82)Mouth2 (18)Stimulation measurements at latest follow-upAmplitude (V) $3.4 \pm 0.6$ (range 2.6-5.0)Pulse width ( $\mu$ s) $133.6 \pm 57.4$ (range 60-210)Frequency (Hz) $143.1 \pm 38.1$ (range 60-185)Follow-up (mo) $23.0 \pm 6.3$ Preoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $9.9 \pm 5.3$ At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.4 \pm 6.8$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	No. of patients	11			
Male2 (18)Female9 (82)Duration of illness (yr) $8.7 \pm 7.5$ (range 1-20)Site of onset-no. (%) $8.7 \pm 7.5$ (range 1-20)Eye9 (82)Mouth2 (18)Stimulation measurements at latest follow-upAmplitude (V)Amplitude (V) $3.4 \pm 0.6$ (range 2.6-5.0)Pulse width ( $\mu$ s)133.6 $\pm 57.4$ (range 60-210)Frequency (Hz)143.1 $\pm 38.1$ (range 60-185)Follow-up (mo)23.0 $\pm 6.3$ Preoperative BFMDRS24.5 $\pm 5.9$ Postoperative BFMDRS24.5 $\pm 5.9$ Postoperative BFMDRS5.3At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.4 \pm 6.8$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	Age at onset (yr)	49.4 ± 9.7 (range 37-69)			
Female9 (82)Duration of illness (yr) $8.7 \pm 7.5$ (range 1-20)Site of onset-no. (%) $Eye$ Eye9 (82)Mouth2 (18)Stimulation measurements at latest follow-upAmplitude (V) $3.4 \pm 0.6$ (range 2.6-5.0)Pulse width (µs) $133.6 \pm 57.4$ (range 60-210)Frequency (Hz) $143.1 \pm 38.1$ (range 60-185)Follow-up (mo) $23.0 \pm 6.3$ Preoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $9.9 \pm 5.3$ At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.3 \pm 5.6$ At 12 months after surgery $3.3 \pm 1.8$	Sex-no. (%)				
Duration of illness (yr) $8.7 \pm 7.5$ (range 1-20)Site of onset-no. (%)Eye9 (82)Mouth2 (18)Stimulation measurements at latest follow-upAmplitude (V) $3.4 \pm 0.6$ (range 2.6-5.0)Pulse width (µs) $133.6 \pm 57.4$ (range 60-210)Frequency (Hz) $143.1 \pm 38.1$ (range 60-185)Follow-up (mo) $23.0 \pm 6.3$ Preoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRSDuring test period9.9 $\pm 5.3$ At 3 months after surgeryAt 6 months after surgery $6.3 \pm 5.6$ At 12 months after surgery $3.3 \pm 1.8$	Male	2 (18)			
Site of onset-no. (%) 9 (82)   Eye 9 (82)   Mouth 2 (18)   Stimulation measurements at latest follow-up 4   Amplitude (V) $3.4 \pm 0.6$ (range 2.6-5.0)   Pulse width (µs) $133.6 \pm 57.4$ (range 60-210)   Frequency (Hz) $143.1 \pm 38.1$ (range 60-185)   Follow-up (mo) $23.0 \pm 6.3$ Preoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $24.5 \pm 5.9$ At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.4 \pm 6.8$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	Female	9 (82)			
Eye 9 (82)   Mouth 2 (18)   Stimulation measurements at latest follow-up   Amplitude (V) $3.4 \pm 0.6$ (range 2.6-5.0)   Pulse width ( $\mu$ s) $133.6 \pm 57.4$ (range 60-210)   Frequency (Hz) $143.1 \pm 38.1$ (range 60-185)   Follow-up (mo) $23.0 \pm 6.3$ Preoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $24.5 \pm 5.9$ At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.4 \pm 6.8$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	Duration of illness (yr)	8.7 ± 7.5 (range 1-20)			
Mouth2 (18)Stimulation measurements at latest follow-upAmplitude (V)3.4 $\pm$ 0.6 (range 2.6-5.0)Pulse width ( $\mu$ s)133.6 $\pm$ 57.4 (range 60-210)Frequency (Hz)143.1 $\pm$ 38.1 (range 60-185)Follow-up (mo)23.0 $\pm$ 6.3Preoperative BFMDRS24.5 $\pm$ 5.9Postoperative BFMDRSDuring test period9.9 $\pm$ 5.3At 3 months after surgery6.4 $\pm$ 6.8At 12 months after surgery6.3 $\pm$ 5.6At 24 months after surgery3.3 $\pm$ 1.8	Site of onset-no. (%)				
Stimulation measurements at latest follow-upAmplitude (V) $3.4 \pm 0.6$ (range 2.6-5.0)Pulse width ( $\mu$ s) $133.6 \pm 57.4$ (range 60-210)Frequency (Hz) $143.1 \pm 38.1$ (range 60-185)Follow-up (mo) $23.0 \pm 6.3$ Preoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $9.9 \pm 5.3$ At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.3 \pm 5.6$ At 12 months after surgery $3.3 \pm 1.8$	Eye	9 (82)			
Amplitude (V) $3.4 \pm 0.6$ (range 2.6-5.0)Pulse width (µs) $133.6 \pm 57.4$ (range 60-210)Frequency (Hz) $143.1 \pm 38.1$ (range 60-185)Follow-up (mo) $23.0 \pm 6.3$ Preoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $9.9 \pm 5.3$ At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.3 \pm 5.6$ At 12 months after surgery $3.3 \pm 1.8$	Mouth	2 (18)			
Pulse width ( $\mu$ s)133.6 ± 57.4 (range 60-210)Frequency (Hz)143.1 ± 38.1 (range 60-185)Follow-up (mo)23.0 ± 6.3Preoperative BFMDRS24.5 ± 5.9Postoperative BFMDRS9.9 ± 5.3At 3 months after surgery8.9 ± 7.7At 6 months after surgery6.3 ± 5.6At 12 months after surgery3.3 ± 1.8	Stimulation measurements at latest follow-up				
Frequency (Hz) $143.1 \pm 38.1$ (range 60-185)Follow-up (mo) $23.0 \pm 6.3$ Preoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $9.9 \pm 5.3$ During test period $9.9 \pm 5.3$ At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.4 \pm 6.8$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	Amplitude (V)	3.4 ± 0.6 (range 2.6-5.0)			
Follow-up (mo) $23.0 \pm 6.3$ Preoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $24.5 \pm 5.9$ During test period $9.9 \pm 5.3$ At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.4 \pm 6.8$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	Pulse width (µs)	133.6 ± 57.4 (range 60-210)			
Preoperative BFMDRS $24.5 \pm 5.9$ Postoperative BFMDRS $9.9 \pm 5.3$ During test period $9.9 \pm 5.3$ At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.4 \pm 6.8$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	Frequency (Hz)	143.1 ± 38.1 (range 60-185)			
Postoperative BFMDRSDuring test period $9.9 \pm 5.3$ At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.4 \pm 6.8$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	Follow-up (mo)	$23.0 \pm 6.3$			
During test period $9.9 \pm 5.3$ At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.4 \pm 6.8$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	Preoperative BFMDRS	24.5 ± 5.9			
At 3 months after surgery $8.9 \pm 7.7$ At 6 months after surgery $6.4 \pm 6.8$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	Postoperative BFMDRS				
At 6 months after surgery $6.4 \pm 6.8$ At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	During test period	9.9 ± 5.3			
At 12 months after surgery $6.3 \pm 5.6$ At 24 months after surgery $3.3 \pm 1.8$	At 3 months after surgery	8.9 ± 7.7			
At 24 months after surgery 3.3 ± 1.8	At 6 months after surgery	$6.4 \pm 6.8$			
	At 12 months after surgery	6.3 ± 5.6			
12 Mo % improvement from baseline (%) 74.5 ± 19.8	At 24 months after surgery	$3.3 \pm 1.8$			
	12 Mo % improvement from baseline	(%) 74.5 ± 19.8			

# Table 3. Summary of BFMDRS in sites

#### RESULTS

The mean BFMDRS total movement scores were the following :  $24.5 \pm 5.9$  at baseline;  $9.9 \pm 5.3$  during the immediate postoperative period of test stimulation;  $8.9 \pm 7.7$  at 3 months after surgery;  $6.4 \pm 6.8$  at 6 months after surgery; 6.3 $\pm$  5.6 at 12 months after surgery; and 3.3  $\pm$  1.8 at 24 months after surgery (Table 2). The mean BFMDRS total movement scores improved by  $59.8 \pm 21.3\%$  during the immediate postoperative period of test stimulation (p < 0.001, Wilcoxin signed rank test),  $63.5 \pm 30.6\%$  at 3 months after surgery (p <(0.001), 74.1 ± 22.3% at 6 months after surgery (p = 0.003), 74.5  $\pm$  19.8% at 12 months after surgery (p < 0.001), and  $85.5 \pm 10.1\%$  at 24 months after surgery (*p* = 0.042) (Table 1, 2). The BFMDRS total movement scores were reduced gradually and the results reached statistical significance in the postoperative period (test period, 3, 6, 12, and 24 months after surgery). There was no statistical difference between 12 months and 24 months (p = 0.075). The mean BFMDRS disability score also improved, from  $6.7 \pm 2.7$  before surgery to  $1.4 \pm 1.2$  at 12 months after surgery, reflecting a 79.1 ± 20.1% improvement. The results reached statistical significance (p = 0.003). At 12 months after surgery, the mean individual BFMDRS movement scores were as follows : for eyes  $6.0 \pm 2.2$  at baseline and  $2.2 \pm 2.1$  at 12 months after surgery, reflecting a 63.3  $\pm$  34.2% improvement (p = 0.005); mouth at baseline  $6.3 \pm 1.9$ , and  $1.2 \pm 1.3$  at 12 months after surgery, reflecting an 80.9  $\pm$  24.8% improvement (p < 0.001); speech/swallowing at baseline 7.9  $\pm$  3.2, and 2.5  $\pm$  1.9 at 12 months after surgery, reflecting a 68.4 ± 43.8% improvement (p = 0.006); and neck 3.3 ± 2.6 at baseline and 0.4 ± 1.2 at 12 months after surgery, reflecting an 87.9 ± 46.7% improvement (p = 0.011) (Table 3). All the results reached statistical significance. The postoperative course in BFMDRS movement scores in each site is shown in Fig. 3.

In our study, five patients had severe blepharospasm (initial eyes BFM subscore 8) and six patients had mild to moderate blepharospasm (initial eyes BFM subscore < 8). The mean total BFMDRS scores in the first group were 24.6  $\pm$  6.1 at baseline and at 12 months after surgery 9.3  $\pm$  5.72, reflecting

							12 mo
Sites	Baseline	Test period	3 mo	6 mo	12 mo	24 mo	% improvement
							from baseline
Eyes	6.0	2.0	2.7	1.7	2.2	0.4	-63.3%
Mouth	6.3	2.7	2.4	1.6	1.2	0.7	-80.9%
Speech/Swallowing	7.9	4.0	3.2	2.6	2.5	2.2	-68.4%
Neck	3.3	1.2	0.6	0.6	0.4	0.0	-87.9%

Wilcoxin signed rank test (paired). All the result reached statistical significance at 12 months in comparison to baseline scores (for eye, p = 0.005; mouth, p < 0.001; speech/ swallowing, p = 0.006; neck, p = 0.011). Significant p value (< 0.05)




Fig. 2. Scatterplots of the final target (the lowest electrode position) at the axial plane. AC : anterior commissure, PC : posterior commissure.




Fig. 3. Postoperative course showing gradual and sustained improvement in Burk-Fahn-Marsden dystonia rating scale (BFMDRS) movement scores in each site. Pre-op : preoperation, Post-op : postoperation.

a 76.7  $\pm$  14.7% improvement. The mean total BFMDRS scores in the second group were 24.5  $\pm$  6.4 at baseline and at 12 months after surgery 3.8  $\pm$  4.5, reflecting an 84.5  $\pm$  19.6% improvement. However, the results between the two groups did not reach statistical significance (*p* = 0.079, Mann-Whitney test).

Five patients in the study had severe oromandibular dystonia (initial mouth BFM subscore 8) and six patients had mild to moderate oromandibular (initial mouth BFM subscore < 8). The mean BFMDRS total movement scores in the first group were 26.4 ± 6.2 at baseline and at 12 months after surgery 5.6 ± 8.2, reflecting an 78.8 ± 25.3% improvement. The mean BFMDRS total movement scores in the second group were 23.0 ± 5.7 at base line and 6.9 ± 2.9 at 12 months after surgery, reflecting a 70.0 ± 13.0% improvement. However, the results between the two groups did not reach statistical significance (p = 0.196, Mann-Whitney test).

Oromanibular dystonia presents as a jaw opening type, a jaw closing type, and as a mixed type. Most patients suffered



Fig. 4. Preoperative (A) and postoperative (B) photographs of patient 7 showing clinical feature of jaw opeining type oromandibular dystonia.

from the jaw closing type<sup>8</sup>. In our study, two patients had the jaw opening type with tongue protrusion and twisting (Fig. 4). The mean BFMDRS total movement scores in this group were 24.0 ± 5.7 at baseline and 5.0 ± 7.1 at 12 months after surgery, reflecting a 79.2 ± 24.9% improvement. The mean BFMDRS total movement scores in the other group with jaw closing were 24.7 ± 6.3 at baseline and 6.6 ± 5.7 at 12 months after surgery, reflecting a 73.3 ± 19.9% improvement. However, the results between the two groups did not reach statistical significance (p = 0.813, Mann-Whitney test).

Nine patients experienced their first symptom in the eyes and two patients in the mouth. The mean BFMDRS total movement scores in the first group were 24.0 ± 5.5 at base line and 6.6 ± 5.7 at 12 months after surgery, reflecting a 73 ± 19.9% improvement. The mean BFMDRS total movement scores in the other group were 27 ± 9.9 at baseline and 5 ± 7.1 at 12 months after surgery, reflecting a 81.5 ± 20.9% improvement. The results between the two groups did not reach statistical significance (p = 0.288, Mann-Whitney test).

We also compared the prognosis of male patients with females, older onset age (> 50 years) with younger (< 50 years), and longer duration (> 7 years) with shorter (< 7 years); however, these factors did not affect the prognosis statistically (p = 0.345, p = 0.508, p = 0.608, Mann-Whitney test).

No significant peri-operative complications were noted. No patient had a permanent major complication due to a hardware-related problem or to chronic stimulation. Five patients reported with transient reversible side effects, such as slowness in their walking, heaviness in their legs, subtle difficulty in speaking and swallowing, fatigue, depression, and general weakness.

### DISCUSSION

The present retrospective analysis of the 11 patients with medically refractory Meige syndrome with a mean follow-up period of 23.1 months contributes to our understanding of the outcome rates of treatment by bilateral GPi-DBS. In our study, the prognosis shows a 59.8% improvement in the BFMDRS total movement scores during the immediate postoperative period of test stimulation, 63.5% improvement at 3 months, 74.1% improvement at 6 months, 74.5% improvement at 12 months, and 85.5% improvement at 24 months postoperatively. The BFMDRS total movement scores were reduced gradually and the results reached statistical significance. The mean disability score was also statistically improved, from 6.7 before surgery to 1.4 at 12 months after surgery, reflecting a 79.1% improvement. Results of these findings are similar to those of earlier study<sup>9</sup>. Ostrem et al.<sup>77</sup> reported the results of bilateral pallidal DBS in six patients with cranial-cervical dystonia showing a 72% improvement in the BFMDRS total movement score at 6 months.

In the present study, the most pronounced improvement in symptoms was oromandibular dystonia (80.9%), followed by speech/swallowing (68.4%), and blepharospasm (63.3%) except for cervical dystonia (87.9%) at 12 months after surgery. However, the results of our findings are inconsistent with a study that reported that blepharospasm and facial dystonia responded to treatment better than speech and swallowing symptoms in six cases that were followed for more than 12 months<sup>4</sup>). This suggests to be either a clinical heterogenous condition of dystonia or a small case series. Nine patients (81.8%) had cervical dystonia. All of them had mobile or phasic type of the cervical dystonia. These results correspond with the results of earlier study which reported that GPi-DBS can improve mobile type cervical dystonia significantly<sup>3</sup>).

The prognostic factors of bilateral GPi-DBS in Meige syndrome have not been established. In the present study, the prognostic factors such as sex, onset age, duration of symptoms, onset site, type of jaw opening or closing, and severity of symptoms of blepharospasm and oromandibular dystonia did not affect the prognosis. More cases and studies will be required to confirm the prognostic factors of GPi-DBS in the treatment of Meige syndrome.

#### CONCLUSION

We conclude that the bilateral GPi-DBS can be an effective and safe treatment option in refractory Meige syndrome despite the varied clinical expressions of this disease. Blepharospasm, oromandibular dystonia, and speech/swallowing all improved with GPi-DBS. The most pronounced improvement in symptoms was oromandibular dystonia, followed by speech/swallowing and blepharospasm. There is no significant difference in outcome according to age, sex, onset site, type, severity, or duration of symptoms.

#### References

- Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J : Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 35 : 73-77, 1985
- Jankovic J : Clinical features, differential diagnosis and pathogenesis of blepharospam and cranial-cervical dystonia in Bosniak L (ed) : Blepharospasm advances in ophthalmic plastic reconstructive surgery. New York : Pergamon Press, 1998, pp 67-82
- Jeong SG, Lee MK, Kang JY, Jun SM, Lee WH, Ghang CG : Pallidal deep brain stimulation in primary cervical dystonia with phasic type : clinical outcome and postoperative course. J Korean Neurosurg Soc 46 : 346-350, 2009
- Jung HH, Chang JW : Surgical management of hemifacial spasm and Meige syndrome in Krames ES, Hunter Peckham P, Rezai AR (eds) : Neuromodulation, ed 1. Elsevier, 2009, Vol 2, pp587-597
- Kupsch A, Benecke R, Müller J, Trottenberg T, Schneider GH, Poewe W, et al. : Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 335 : 1978-1990, 2006
- Meige H : Les convulsions de la face, une forme clinique de convulsion faciale, bilatérale et médiane. Rev Neurologique (Paris) 20 : 437-443, 1910
- Ostrem JL, Marks WJ Jr, Volz MM, Heath SL, Starr PA : Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome). Mov Disord 22 : 1885-1891, 2007
- Tan EK, Jankovic J : Botumlinum toxin A in patients with oromandibular dystonia : long-term follow-up. Neurology 53 : 2102-2107, 1999
- 9. Vercueil L, Pollak P, Fraix V, Caputo E, Moro E, Benazzouz A, et al. : Deep brain stimulation in the treatment of severe dystonia. J Neurol 248:695-700, 2001
- Vidailhet M, Vercueil L, Houeto JL, Krystkowiak P, Benabid AL, Cornu P, et al. : Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 352 : 459-467, 2005